Abbott and Flatiron Health have integrated Abbott's Precision Oncology tests into Flatiron's OncoEMR platform, enabling over 4,700 oncology providers across 1,600+ US community cancer centers to order tests and receive results directly within their clinical workflow. This integration includes tests like Oncotype DX and Riskguard, helping clinicians make faster, more informed treatment decisions while reducing administrative tasks. The move broadens access to advanced cancer diagnostics where most US cancer care occurs, supporting personalized patient care and improving workflow efficiency.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
